Literature DB >> 14602855

In vivo evidence of endothelial injury in chronic obstructive pulmonary disease by lung scintigraphic assessment of (123)I-metaiodobenzylguanidine.

Tsuyoshi Arao1, Noriaki Takabatake, Makoto Sata, Shuichi Abe, Yoko Shibata, Tsuguo Honma, Kazuei Takahashi, Akio Okada, Yasuchika Takeishi, Isao Kubota.   

Abstract

UNLABELLED: Scintigraphic evaluation of (123)I-metaiodobenzylguanidine ((123)I-MIBG) in the lungs is considered to recognize endothelial cell lesions. The aim of this study was to clarify the involvement of the pulmonary microvascular injury in the pathogenesis of chronic obstructive pulmonary disease (COPD).
METHODS: We investigated lung (123)I-MIBG kinetics and clinical indices in 25 COPD patients and 12 control subjects. Mean uptake ratios of lung to mediastinum (L/M) were calculated in anterior planer images at 30 min (early image) and 270 min (delayed image) after intravenous injection of (123)I-MIBG. Pulmonary mean washout rate (WR) of the (123)I-MIBG was also calculated.
RESULTS: The L/M ratios in both early and delayed images of COPD patients, as well as its WR, were significantly lower than those of the control subjects (L/M early: 1.26 +/- 0.18 vs. 1.54 +/- 0.11, P < 0.0001; L/M delayed: 1.20 +/- 0.12 vs. 1.33 +/- 0.09, P < 0.001; WR: 27.4% +/- 5.3% vs. 34.2% +/- 5.7%, P < 0.01). There were significant relationships between lung WR of the (123)I-MIBG and other diagnostic tests for the severity of COPD, such as forced expiratory volume in 1 s (% FEV(1.0): r = 0.386, P < 0.05), carbon monoxide diffusing capacity/alveolar volume (DL(CO)/V(A): r = 0.449, P < 0.01), arterial blood oxygen pressure (PaO(2): r = 0.474, P < 0.01), alveolar-arterial oxygen tension gradient [A-a]DO(2) (r = -0.446, P < 0.01), and percentage of low-attenuation area (r = -0.458, P < 0.01) in the study population.
CONCLUSION: Because lung WR of the (123)I-MIBG is considered to be independent of an alteration of the pulmonary vascular surface area, these results suggest that the microvascular endothelial cell injury plays a significant role in the pathogenesis of COPD.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14602855

Source DB:  PubMed          Journal:  J Nucl Med        ISSN: 0161-5505            Impact factor:   10.057


  14 in total

1.  Vascular dysfunction and chronic obstructive pulmonary disease: the role of redox balance.

Authors:  Stephen J Ives; Ryan A Harris; Melissa A H Witman; Anette S Fjeldstad; Ryan S Garten; John McDaniel; D Walter Wray; Russell S Richardson
Journal:  Hypertension       Date:  2013-12-09       Impact factor: 10.190

2.  Involvement of pulmonary endothelial cell injury in the pathogenesis of pulmonary fibrosis: clinical assessment by 123I-MIBG lung scintigraphy.

Authors:  Noriaki Takabatake; Tsuyoshi Arao; Makoto Sata; Shuichi Abe; Sumito Inoue; Yoko Shibata; Yasuchika Takeishi; Isao Kubota
Journal:  Eur J Nucl Med Mol Imaging       Date:  2004-09-23       Impact factor: 9.236

3.  Significance of I-123 metaiodobenzylguanidine (¹²³I-MIBG) lung activity in subjects with heart failure in comparison to healthy control subjects.

Authors:  Myron C Gerson; Alok K Dwivedi; Mouhamad Abdallah; Rakesh Shukla; Arnold F Jacobson
Journal:  J Nucl Cardiol       Date:  2013-04-30       Impact factor: 5.952

4.  Age-related decrease in cardiopulmonary adrenergic neuronal function in children as assessed by I-123 metaiodobenzylguanidine imaging.

Authors:  Wengen Chen; Elias H Botvinick; Abass Alavi; Yifan Zhang; Steven Yang; Rodolfo Perini; Hongming Zhuang
Journal:  J Nucl Cardiol       Date:  2008 Jan-Feb       Impact factor: 5.952

5.  Cardio-pulmonary involvement in pulmonary arterial hypertension: A perfusion and innervation scintigraphic evaluation.

Authors:  Alessia Gimelli; Nicola Riccardo Pugliese; Michelangelo Bertasi; Edoardo Airò; Carolina Bauleo; Bruno Formichi; Renato Prediletto; Paolo Marzullo; Simonetta Monti
Journal:  J Nucl Cardiol       Date:  2019-03-22       Impact factor: 5.952

6.  Predictors of outcome in patients with de novo diagnosis of heart failure with reduced ejection fraction: Role of combined myocardial and lung Iodine-123 Meta-Iodobenzylguanidine imaging.

Authors:  Angelo Silverio; Maria Vincenza Polito; Leonardo Pace; Federica D'Auria; Gennaro Vitulano; Massimo Scarano; Rodolfo Citro; Gennaro Galasso; Federico Piscione
Journal:  J Nucl Cardiol       Date:  2019-02-13       Impact factor: 5.952

7.  The relationship between serum uric acid and spirometric values in participants in a health check: the Takahata study.

Authors:  Yasuko Aida; Yoko Shibata; Daisuke Osaka; Shuichi Abe; Sumito Inoue; Koji Fukuzaki; Yoshikane Tokairin; Akira Igarashi; Keiko Yamauchi; Takako Nemoto; Keiko Nunomiya; Hiroyuki Kishi; Masamichi Sato; Tetsu Watanabe; Tsuneo Konta; Sumio Kawata; Takeo Kato; Isao Kubota
Journal:  Int J Med Sci       Date:  2011-08-05       Impact factor: 3.738

8.  Relationships between values of antibodies to several connective tissue disease autoantigens and pulmonary function in a Japanese general population: the Takahata study.

Authors:  Hiroshi Nakano; Yoko Shibata; Sumito Inoue; Akira Igarashi; Keiko Yamauchi; Shuichi Abe; Masamichi Sato; Yasuko Aida; Keiko Nunomiya; Tomomi Kimura; Takako Nemoto; Tetsu Watanabe; Tsuneo Konta; Yoshiyuki Ueno; Takeo Kato; Takamasa Kayama; Isao Kubota
Journal:  PLoS One       Date:  2013-12-03       Impact factor: 3.240

9.  Retrospective analysis of the relationship between decline in FEV(1) and abdominal circumference in male smokers: the Takahata study.

Authors:  Masamichi Sato; Yoko Shibata; Shuichi Abe; Sumito Inoue; Akira Igarashi; Keiko Yamauchi; Yasuko Aida; Hiroyuki Kishi; Keiko Nunomiya; Hiroshi Nakano; Kento Sato; Tetsu Watanabe; Tsuneo Konta; Yoshiyuki Ueno; Takeo Kato; Takamasa Kayama; Isao Kubota
Journal:  Int J Med Sci       Date:  2012-12-05       Impact factor: 3.738

10.  Cardiac sympathetic dysautonomia in children with chronic kidney disease.

Authors:  Viviane Parisotto; Eleonora Moreira Lima; José Maria Penido Silva; Marcos Roberto de Sousa; Antonio L Ribeiro
Journal:  J Nucl Cardiol       Date:  2008 Mar-Apr       Impact factor: 3.872

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.